clinical trial · NCT07159243
Evaluate the Efficacy and Safety of HL-1186 in Patients With Diabetic Peripheral Neuropathic Pain
Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.·phase2·not yet recruiting·n = 180
Diabetic Peripheral Neuropathic PainHL-1186HL-1186HL-1186 placebo
brief summary
This is a multi-center, randomized, double-blind, placebo-controlled study design evaluating the safety, efficacy, and PK parameter of HL-1186 tablet for diabetic peripheral neuropathic pain.
started
Sep 1, 2025
primary completion
Oct 1, 2026
completion
Oct 1, 2026
last updated
Sep 8, 2025
official title
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Parallel-designed Clinical Study to Evaluate the Efficacy and Safety of HL-1186 in Patients With Diabetic Peripheral Neuropathic Pain
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol